Abstract | PURPOSE: METHODS: We reviewed the English literature for phase II trials of therapies for recurrent malignant glioma conducted between January 2000 and September 2010. The search was supplemented by a review of articles published prior to 2000 on chemotherapy regimens that had shown activity on recurrent gliomas. RESULTS: CONCLUSION: Unfortunately, progress in the development of new and more effective chemotherapy agents has been very limited and leaves the clinician treating high-grade glioma patients at relapse with few good options. The suggested algorithm is our objective evaluation of the currently existing knowledge. Hopefully, the ongoing phase II and III trials will provide us the needed chemotherapy agents in the years to come.
|
Authors | Athanassios P Kyritsis, Victor A Levin |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 67
Issue 5
Pg. 971-83
(May 2011)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 21442438
(Publication Type: Journal Article, Review)
|
Chemical References |
- Angiogenesis Inhibitors
- Antineoplastic Agents, Alkylating
- Dacarbazine
- Temozolomide
|
Topics |
- Algorithms
- Angiogenesis Inhibitors
(therapeutic use)
- Antineoplastic Agents, Alkylating
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Brain Neoplasms
(drug therapy, genetics)
- Clinical Trials, Phase II as Topic
- Dacarbazine
(analogs & derivatives, therapeutic use)
- Genotype
- Glioma
(drug therapy, genetics)
- Humans
- Molecular Targeted Therapy
- Neoplasm Recurrence, Local
(drug therapy)
- Temozolomide
- Treatment Failure
|